Skip to main content
. 2021 Jan 26;87(8):3206–3217. doi: 10.1111/bcp.14736

FIGURE 3.

FIGURE 3

Circulating concentration of A, alanine transaminase (ALT; IU/L) and B, K18 (U/L) for sequential samples in patients within the SAEFRIF trial. Black dots show patients with normal ALT throughout treatment, red points show patients whose ALT rises >50 IU/L during treatment, blue points show patients whose ALT falls from >50 IU/L upon starting treatment. Dotted line on (A) ALT = 50 IU/L